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Abstract: The aim of this review was to discuss the current literature regarding the utility of 
noninvasive imaging in diagnosis and management of stable coronary artery disease (CAD) 
including recent data from large randomized trials assessing diagnosis and prognosis. Current 
guidelines recommend revascularization in patients with refractory angina and in those with 
potential prognostic benefit. Appropriate risk stratification through noninvasive assessment is 
important in ensuring patients are not exposed to unnecessary invasive coronary angiograms. 
The past 20 years have seen an unprecedented expansion in noninvasive imaging modalities 
for the assessment of stable CAD, with cardiovascular magnetic resonance and computed 
tomography complementing established techniques such as myocardial perfusion imaging, 
echocardiography and exercise electrocardiogram. In this review, we examine the current 
state-of-the-art in noninvasive imaging to provide an up-to-date analysis of current investiga-
tion and management options.
Keywords: angina, noninvasive imaging, SPECT, stress echo, cardiovascular magnetic reso-
nance, CT coronary angiography
Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide, and despite 
advances in diagnosis and treatment, coronary artery disease (CAD) remains the 
number 1 cardiovascular (CV) cause of mortality and morbidity.1 Given the increas-
ing burden of CAD worldwide, diagnostic techniques for identification of CAD 
are particularly important. In routine clinical practice, the definitive diagnosis of 
significant CAD is typically made during invasive coronary angiography (ICA), with 
significant disease being historically defined as ≥50% stenosis in the left main stem 
or ≥70% stenosis in other coronary arteries.2 The past 20 years have seen a rapid 
expansion in the number of different noninvasive imaging modalities used for the 
assessment of stable CAD. In addition to established noninvasive techniques such 
as the exercise electrocardiogram (exECG), myocardial nuclear perfusion imaging 
(MPI – most commonly single-photon emission computed tomography [SPECT]) 
and stress echocardiography, newer techniques such as CV magnetic resonance 
(CMR) and computed tomography (CT) are likely to have a significant clinical util-
ity in the future. The aim of this review was to discuss the current literature on the 
efficacy of noninvasive imaging tests compared to ECG and MPI in the diagnosis 
of stable CAD.
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Current recommendations for 
diagnostic testing in stable CAD
Current European and American guidelines for the assess-
ment of stable CAD2,3 recommend a common approach. 
First, an assessment of the pretest probability (PTP) of CAD 
is made on the basis of clinical history, examination and 
basic tests such as the ECG. Following this assessment of 
PTP, a decision on further investigation should be taken. In 
patients with high PTP (>85%), no further noninvasive test-
ing is required to make the diagnosis of CAD, and ICA can 
be performed for risk stratification. Conversely, in patients at 
low risk (PTP < 15%), the likelihood of CAD is so low that 
consideration should be directed toward non-CAD causes 
of chest pain. If CAD still needs to be excluded in patients 
with low PTP, CT coronary angiography (CTCA) has a high 
negative predictive value and is useful in this group.
Further noninvasive testing for CAD is particularly 
required in the intermediate-risk group (PTP 15–85%). This 
group comprises the majority of patients referred to the clinic 
for evaluation of chest pain, and therefore, imaging plays a 
key role in risk stratification and management. The main aim 
of noninvasive testing is to select patients likely to benefit 
from ICA and revascularization. The Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation 
(COURAGE) trial demonstrated that although percutaneous 
coronary intervention (PCI) in addition to optimal medical 
therapy (OMT) reduced frequency of angina compared to 
OMT alone, there was no reduction in death, nonfatal myo-
cardial infarction [MI] or hospitalization for acute coronary 
syndrome (ACS).4 This trial, along with evidence from the 
Bypass Angioplasty Revascularization Investigation 2 Dia-
betes (BARI-2D) trial and from meta-analyses,5–7 has led to 
the general guideline recommendation that invasive angiog-
raphy revascularization with PCI should only be performed 
in patients whose symptoms are refractory to OMT, or in 
those in whom there is likely to be prognostically significant 
disease. In addition, however, ICA can also be performed for 
“softer” reasons, in particular, to provide diagnostic clarity 
and reassurance.
In light of these studies, the role of noninvasive imaging in 
guiding selection of patients for ICA has become increasingly 
important. We now discuss each of these noninvasive tech-
niques in turn. Table 1 summarizes all discussed modalities.
exECG
The exECG is one of the most widely studied and utilized 
techniques for the identification of ischemia. Exercise can be 
performed using either treadmill or exercise bicycle (supine 
or upright). The most commonly conducted technique for 
the exECG is the Bruce protocol.8 This involves exercise 
increased incrementally at 3-minute intervals until the patient 
reaches a desired target (most commonly heart rate of 85% 
of predicted heart rate for age) or until the patient can no 
longer continue. Continuous 12-lead ECG monitoring and 
noninvasive blood pressure are measured throughout. Typical 
end points suggestive of the presence of ischemia include ST 
segment elevation, ST segment depression (downsloping or 
flat and >2 mm), development of ventricular arrhythmias or 
reproduction of angina symptoms. exECG has the advantage 
of being cheap and relatively easy to perform and interpret 
as well as providing rapidly available clinically useful infor-
mation which can be used to direct further investigation or 
reassure patients.
One of the main limitations of exECG is the presence of 
resting ECG abnormalities such as left bundle branch block 
(LBBB). Lack of physical fitness also may provide inconclu-
sive results. In addition, there is the potential for induction 
of ventricular arrhythmias.
exECG performs moderately for the diagnosis of signifi-
cant CAD. A meta-analysis of 34 studies including more than 
3,000 patients by Banerjee et al8 reported that a negative test 
still leads to a diagnosis of CAD in 37% of men and 18% of 
women. exECG also has a significant amount of prognostic 
data, with a negative, low-risk test conferring a very good 
prognosis.10,11 In addition to the assessment of ischemia, 
functional capacity on exercise testing also provides impor-
tant prognostic information, with patients able to exercise to 
10 metabolic equivalents (METs) having an extremely low 
risk of major adverse CV events independent of the amount 
of ischemia.12–14
Despite these limitations and its downgrading in recent 
guidelines, exECG continues to be used in many centers due 
to its easy availability and clinicians’ confidence with its 
performance. It is also still important in other settings such 
as in exercise-induced arrhythmias.
Nuclear imaging
Although encompassing a number of techniques, the most 
commonly used nuclear imaging technique is SPECT. This 
technique can be performed using either exercise or pharma-
cological methods (using vasodilators such as dipyridamole) 
and relies upon the uptake of radioactive tracers into the 
myocardium at rest and stress. The most commonly used 
tracers are thallium and technetium. The heart is scanned 
using a gamma camera to assess the perfusion of the tracer 
into the myocardium. A positive test for inducible ischemia 
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is obtained when there is a relative reduction in uptake of 
the tracer at stress due to the reduction in blood flow to the 
ischemic territory compared to normal tissue which becomes 
hyperemic. SPECT is also able to provide information on 
viability as areas of previous MI which are nonviable will 
display a fixed perfusion defect with a reduction in tracer 
uptake at both rest and stress. SPECT is also able to provide 
an estimate of left ventricular function.
Table 1 Summary of non-invasive imaging modalities for assessment of suspected stable angina
Modality Advantages Disadvantages Diagnostic accuracy Ionizing 
radiation dose
exECG •	 Cheap
•	 Easy to perform
•	 Requires little post-processing/
analysis
•	 Extensive long-term data
•	 Relatively poor diagnostic accuracy
•	 Limited by patient’s physical capacity
Sensitivity: 60%
Specificity: 76%9
Nil
MPS/
SPECT
•	 Extensive long-term prognostic data
•	 FFR (current invasive gold standard) 
initially validated against SPECT
•	 Can be performed with exercise, 
vasodilator or dobutamine stress
•	 Offers functional information
•	 PET/CT has potential to offer 
anatomical information in addition to 
functional ischemia assessment
•	 Radiation
•	 Difficulty in the assessment of balanced 
ischemia
•	 False positives in LBBB due to partial 
volume effects
Per vessel47
Sensitivity: 61% (vs. FFR)
Specificity: 84% (vs. FFR)
Per patient47
Sensitivity: 74%
Specificity: 79% (vs. FFR)
7.2 mSv75
Stress 
echo
•	 Nonionizing
•	 Extensive long-term data
•	 Relatively fast to perform
•	 Information on LV function and valves
•	 Viability assessment possible with 
dobutamine
•	 Exercise limited by patient’s physical 
capacity
•	 Despite use of contrast views may still 
be suboptimal
•	 False positives with LBBB
•	 Dobutamine not as physiological as 
exercise
Per patient47
Sensitivity: 69%
Specificity: 84% (vs. FFR)
Nil
CMR •	 Nonionizing
•	 Gold standard for noninvasive 
assessment of ventricle mass and 
function
•	 Offers viability assessment with the 
use of LGE imaging
•	 Offers assessment of valves and 
extra-cardiac structures
•	 Able to assess the heart in any plane
•	 Expensive
•	 Expertise not yet widely available in all 
centers
•	 Unable to perform in patients with 
claustrophobia or renal impairment 
(eGFR <30 mL/min)
•	 Image quality may be degraded by 
arrhythmia/tachycardia, breath holding
•	 Relatively time-consuming
•	 MR angiography not yet at the required 
resolution to offer coronary angiography
Per vessel47
Sensitivity: 87%
Specificity: 91% (vs. FFR)
Per patient47
Sensitivity: 89%
Specificity: 87% (vs. FFR)
Nil
CTCA •	 Excellent anatomical detail
•	 Particularly useful as a rule-out test 
due to high sensitivity and low false-
negative rate
•	 Able to offer some information on 
function and valves
•	 Readily available on most modern CT 
scanners with minimal upgrading
•	 Also offers extra-cardiac assessment 
such as “triple rule-out” test
•	 Radiation (although if optimal is 
equivalent invasive coronary angiogram)
•	 No ventricular functional assessment 
unless retrospective gating is used with a 
consequent increase in radiation dose
•	 Techniques to provide functional 
assessment of ischemia are not yet ready 
for routine clinical use (CT perfusion, 
FFR-CT)
•	 Image quality very dependent on 
optimization of patient factors (heart 
rate/rhythm, breath holding)
•	 Caution in patients with renal 
impairment
Per vessel76
Sensitivity: 91%
Specificity: 58% (vs. FFR)
Per patient76
Sensitivity: 90%
Specificity: 39% (vs. FFR)
1–3 mSv56,78
Note: Median ionizing radiation dose for invasive coronary angiography is 7.4 mSv.78
Abbreviations: CMR, cardiovascular magnetic resonance; CT, computed tomography; CTCA, CT coronary angiography; exECG, exercise echocardiography; eGFR, 
estimated glomerular filtration rate; FFR, fractional flow reserve; LBBB, left bundle branch block; LGE, late gadolinium enhancement; LV, left ventricular; MPS, myocardial 
perfusion scintigraphy; MR, magnetic resonance; PET, positron emission tomography; SPECT, single-photon emission computed tomography.
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One limitation of SPECT is in the assessment of “bal-
anced ischemia.”15 Because interpretation of the study relies 
on comparison of ischemic areas to normal areas, in patients 
(such as those with significant triple vessel disease) where 
there is widespread ischemia throughout the myocardium, 
there is the possibility of incorrectly reporting a scan as 
showing no inducible ischemia when in fact all areas are 
relatively underperfused during stress, thus causing a false-
negative study.
A further limitation is caused by the relatively high radia-
tion dose, which most recently has been reported as around 
7 mSv.16 Furthermore, many of the commonly used tracers 
take some time to leave the myocardium. Given this, many 
protocols involve the initial acquisition of stress images, with 
rest images taken at a later interval (depending on the tracer 
this can be up to 1 week later), thus meaning that results can 
be delayed as well as the study involving two visits for the 
patient. SPECT is also affected by LBBB. Because the septum 
is dyskinetic and contracts at a slightly different time to the 
lateral wall, the septum may not thicken at the time of image 
acquisition. Because the septum appears thinner, tracer uptake 
in the area may appear less, giving the impression of left ante-
rior descending artery (LAD) territory ischemia. This is less 
of an issue using vasodilators rather than exercise however.17
Despite these limitations, there is a wealth of diagnostic 
and prognostic information on the use of SPECT for the 
assessment of stable CAD.
One important study on the prognosis of stable CAD 
patients using SPECT was the COURAGE nuclear substudy.18 
This was an observational substudy of the COURAGE trial 
in which 314 patients underwent SPECT imaging at baseline 
and at 6–18 months post randomization. The study found that 
patients who underwent PCI + OMT had a greater reduction 
in ischemia than those who had OMT alone. There was also 
a trend to improved outcomes, with patients who had no 
residual ischemia having no clinical events. This substudy 
was underpowered for clinical events, however, and so the 
question of ischemia burden and using PCI to improve prog-
nosis is still uncertain.
Another nuclear imaging modality that has recently been 
studied for use in stable CAD is positron emission tomogra-
phy (PET). One particular advantage of this technique is that 
it gives the ability to measure absolute myocardial blood flow, 
thus avoiding problems with balanced ischemia.19 Coronary 
flow reserve is then calculated from the difference in blood 
flow in stress and rest.20 In addition, it can be combined with 
CT to provide both functional and anatomical assessment of 
CAD. The most common PET tracers are rubidium-82 and 
13N-labeled ammonia, although various other tracers can 
be used. A meta-analysis by Mc Ardle et al20 reported an 
increased diagnostic accuracy compared to SPECT for diag-
nosis in patients with suspected CAD, with a sensitivity of 
90% and specificity of 95%. There have also been some recent 
data on prognosis using PET, with several studies reporting a 
significant increase in adverse events in patients with reduced 
coronary flow reserve.22–24 PET using rubidium-82 has been 
shown to provide incremental prognostic value above clini-
cal variables in a series of 1,432 patients undergoing scans, 
with an increasing burden of ischemia being associated with 
worse outcome.25
Despite these benefits, PET remains predominantly a 
research tool, with availability and expertise the predominant 
limitations to more widespread clinical use.
Stress echocardiography
Alongside SPECT, stress echocardiography is the most com-
monly used technique for the assessment of stable CAD. It 
can be performed using either exercise (treadmill or bicycle) 
or using pharmacological stress with dobutamine. Bicycle 
exercise has the advantage of allowing acquisition of images 
at peak exercise if performed while supine, whereas cycling 
in the upright position or on a treadmill requires the patient 
to be repositioned to an optimal position to obtain adequate 
echo images. Continuous 12-lead ECG monitoring is usu-
ally also performed. Of course, echocardiography remains 
the “workhorse” of cardiology, providing rapid assessment 
of ventricular volumes, function and assessment of valves. 
During stress echo, in ischemic segments, the wall motion 
abnormalities develop at peak exercise which are not present 
at rest (with wall motion abnormalities present at rest which 
do not improve on exercise suggestive of nonviable tissue). 
In addition, hibernating myocardium is associated with an 
improvement in wall motion on exercise. Exercise echocar-
diograph also provides a physiologically accurate assessment 
of the effects of exercise on cardiac function. This may be 
particularly important in the setting of associated dyspnea, 
which may be caused by exercise-induced or exacerbated 
mitral regurgitation, left ventricular outflow tract obstruction 
or pulmonary hypertension.
Dobutamine stress echocardiography (DSE) can also be 
performed. This has the advantage of being able to be used in 
patients unable to exercise. Unfortunately, some of the physi-
ological assessment benefits (such as in exercise-induced 
pulmonary hypertension) are more difficult to interpret 
when dobutamine is used. Typical protocols involve the use 
of “high-dose” dobutamine (as opposed to “low dose” in 
patients with aortic stenosis), with increasing increments of 
dobutamine up to a usual maximum of 40 mg/kg/min, with the 
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additional use of atropine if target heart rate is not reached. 
One advantage of DSE is the assessment of viability, which 
is more validated than with exercise echo. This relies on a 
bimodal change in wall motion, with ischemic but viable 
segments of myocardium typically initially improving in 
function at low doses of dobutamine (10–20 mg/kg/min) 
before function worsens again at high doses. This is because 
at low doses dobutamine initially acts as an inotropic agent, 
improving myocardial contractility, whereas at high doses its 
chronotropic and vasodilator effects are more predominant. 
In contrast, in nonviable tissue, wall motion remains impaired 
at all doses.26
Stress echo performs reasonably for the diagnosis of 
CAD, with all techniques performing similarly. Sensitivi-
ties are 85%, 80% and 78% and specificities are 77%, 86% 
and 91% for exercise, dobutamine and dipyridamole stress, 
respectively.27 While these values are not too different to 
SPECT,28 they are significantly better than exECG.29 In 
terms of prognosis, a normal stress echo has been associated 
with a mortality rate of around 1% per year in several large 
observational studies.30–33
Of course, there are limitations with stress echocardiog-
raphy. First, as with resting echocardiography, scan quality 
can be limited by the patient body habitus and inability to 
obtain suitable windows. This difficulty is often exacerbated 
at the high heart rates caused by exercise. Endocardial border 
definition can be improved by the addition of left ventricular 
contrast, and many centers use this routinely. Contrast can 
also be used to provide an assessment of myocardial perfu-
sion, although this is not typically used in standard clinical 
practice.34–36 Nevertheless, in some patients, despite consid-
erable time and effort, adequate images are not available. A 
further limitation with the use of dobutamine is the potential 
for ventricular arrhythmias; thus, DSE is usually performed 
with a clinician and resuscitation facilities available.
Another limitation with stress echocardiography is that 
analysis is often qualitative, with a reviewer making a judg-
ment call as to the presence and severity of any wall motion 
abnormality. Quantitative measures of wall motion using 
speckle tracking have been tested; however, their utility is 
still to be confirmed, particularly in the posterior circula-
tion. Overall, speckle tracking does not appear to improve 
diagnostic accuracy sufficiently to mandate its incorporation 
into routine clinical practice.37,38
Three-dimensional (3D) echocardiography has some 
theoretical benefits, including faster acquisition (ability to 
obtain multiple planes in one scan) and more accurate assess-
ment of ventricular volumes and function. 3D echo may be 
more accurate than 2D, particularly in the LAD territory.39,40 
Again, there are no large trials to strongly support its routine 
use, and it still remains predominantly a technique used in 
specialist centers.
CMR
CMR has become increasingly utilized in clinical cardiology 
over the past 2 decades. CMR has a particular advantage 
in that it is able to offer noninvasive imaging in any plane 
without any limitations due to lungs or ribs and avoiding 
nonionizing radiation. The most useful technique for the 
assessment of stable CAD is stress CMR. Although there 
have been reports of exercise stress,41,42 stress CMR is tra-
ditionally performed using pharmacological stress. Both 
vasodilator (typically using adenosine or regadenoson) and 
dobutamine stress have been used. Vasodilator methods 
involve the administration of intravenous gadolinium contrast 
during vasodilator infusion, with the presence of perfusion 
defects (seen as subendocardial hypointense areas) in isch-
emic territories during peak hyperemia, typically defined as 
a 15 mmHg drop in systolic blood pressure and an increase 
in heart rate. Dobutamine stress CMR, on the other hand, 
uses a similar principle to that of DSE, relying on the dem-
onstration of wall motion abnormalities in the presence of 
ischemia.43 Imaging of perfusion is commonly performed in 
three short-axis planes to obtain a 16-segment model, while 
wall motion abnormalities using dobutamine can also be 
imaged in long-axis planes.
In routine clinical practice, the assessment of perfusion 
defects by CMR is most commonly qualitative, with visual 
assessment by the operator of the presence and extent of isch-
emia. More recently, several groups have conducted research 
on quantitative measures of perfusion. These are either semi-
quantitative, using the difference in signal intensity between 
areas of the myocardium, or fully quantitative, measuring 
absolute blood flow using mathematical modeling.44 The 
use of qualitative measures appears to improve diagnostic 
accuracy; however, it does require further post-processing 
which makes its routine clinical use less attractive currently.45
CMR stress perfusion appears to have better diagnostic 
accuracy than stress echo and SPECT with a meta-analysis by 
Jaarsma et al46 reporting a sensitivity of 89% and specificity 
of 76% compared to ICA with visual assessment and a more 
recent meta-analysis by Takx et al47 reporting a sensitivity of 
89% and specificity of 87% at the per-patient level compared 
to fractional flow reserve (FFR). There have also been a 
number of randomized controlled trials performed compar-
ing CMR and SPECT. The Magnetic Resonance Imaging for 
Myocardial Perfusion Assessment in Coronary artery disease 
Trial (MR-IMPACT) trial compared adenosine stress CMR 
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vs. SPECT in 234 patients in 18 centers. The authors found 
that CMR performed better than SPECT when an optimal 
gadolinium dose (0.1 mmol/kg) was used, suggesting at least 
that it was a viable alternative to SPECT.48
The CMR and single-photon emission CT for the diagno-
sis of coronary heart disease (CE-MARC trial) by Greenwood 
et al48 was a trial conducted in two UK centers to determine 
the diagnostic accuracy of CMR (including adenosine stress, 
magnetic resonance [MR] angiography and late gadolinium 
enhancement [LGE] imaging at 1.5 T) vs. SPECT in the 
diagnosis of stable angina with a gold standard of ICA. In this 
trial, 752 patients judged to be at intermediate risk of CAD 
were randomized to CMR or SPECT. The authors again found 
that CMR had superior diagnostic accuracy to SPECT (CMR: 
sensitivity 86.5%, specificity 83.4%; SPECT: sensitivity 
66.5%, specificity 82.6%), although they did find that MR 
angiography did not add any significant diagnostic benefit. 
These results were replicated in the multicenter, multi-vendor 
MR-IMPACT II, which again showed that adenosine stress 
CMR was superior to SPECT.50
While these studies suggested that CMR was at least as 
good, if not better than SPECT, there was still some doubt as to 
whether the cost and expertise required were worth investing in. 
The CE-MARC 2 trial, which randomized patients to a CMR-
guided strategy, SPECT or UK National Institute for Health 
and Care Excellence guideline recommendation found that 
CMR was equivalent to SPECT and that both strategies reduced 
unnecessary angiography, the primary outcome of the trial.51
One important factor in these large randomized trials was 
the use of ICA as the “gold standard.” As discussed earlier, 
FFR assessment of ischemia is now accepted as the optimal 
measure of coronary lesion significance. The MR-INFORM 
trial was a multicenter trial comparing adenosine stress CMR 
at 1.5 T vs. FFR in patients with suspected stable angina.52 The 
study showed that CMR was non-inferior to FFR, with both 
conferring ≤4% risk of major adverse cardiovascular events 
within 1 year, providing some prognostic data. In addition, 
only 37 out of 454 patients (8.1%) in the CMR-guided arm had 
a negative invasive angiogram (48.8% had a negative CMR 
and did not proceed to invasive testing). The full results of the 
MR-INFORM study are yet to be reported; however, these 
preliminary results suggest that adenosine stress CMR could 
well be a useful technique in the setting of stable angina, with 
some strong prognostic data also.
Beyond the improvement in imaging quality compared 
to echocardiography,53 CMR has several other advantages. 
First, CMR is currently accepted as the noninvasive gold 
standard for the assessment of cardiac structure and function. 
This allows clearer assessment of wall motion abnormalities 
as well as providing further diagnostic information. Second, 
the use of gadolinium contrast also allows the assessment 
of myocardial fibrosis and scarring. Imaging performed 
10–15 minutes after intravenous contrast injection, known as 
LGE imaging, can demonstrate areas of myocardial infarct 
scar. The presence of an infarct-type pattern can help in the 
differentiation between ischemic and non-ischemic cardio-
myopathy, while the transmural extent of the infarct scar can 
be used to determine myocardial viability.54
Nevertheless, CMR has some limitations. The technique 
itself is relatively time-consuming, expensive and not readily 
available in all centers. In addition, not all patients are able to 
tolerate the scan, either due to claustrophobia or inability to 
breath hold adequately. Gadolinium contrast should be used 
with caution and only when strictly necessary in patients with 
an estimated glomerular filtration rate of <30 mL/min due 
to the risk of nephrogenic systemic fibrosis. Finally, image 
quality may be degraded by arrhythmia, although techniques 
such as real-time imaging can be used to mitigate this.
Cardiac CT (CCT)
Although CCT is a noninvasive imaging technique, it differs 
from all of the previously discussed techniques as it is a pre-
dominantly anatomical technique. CCT commonly refers to 
two different modalities – calcium scoring and CTCA. Both 
are carried out using ECG gating to minimize cardiac motion 
artifact, with images usually acquired in diastole where the 
heart is at its most still. In addition, breath holding is used 
to minimize respiratory motion artifact.
CT calcium scoring is performed without contrast. With 
modern 64-slice scanners, imaging is usually acquired in 
one breath hold. The noncontrast study is analyzed using 
rapid post-processing software to measure the amount of 
coronary calcium. The most commonly used scoring method 
is the Agatston score which takes into account the size and 
radiographic density of the plaque to provide a score which 
reflects the coronary calcified plaque burden.55 The presence 
of coronary artery calcification does reflect the burden of CV 
risk; however, not all significant obstructive coronary lesions 
are calcified; in contrast, heavily calcified coronary arteries 
can often be non-obstructed, hence calcium scoring alone 
cannot be used as a diagnostic tool in stable angina. Indeed, 
calcium scoring has fallen out of favor in recent guidelines.2
Currently, CTCA is the preferred method of CCT imaging. 
Current-generation 64-slice CT scanners have reduced con-
cerns about radiation dose – mean radiation dose for one CCT 
is 1–2 mSv with appropriate scan optimization.56 Attaining 
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these doses requires the patients to have slow (<60 bpm), regu-
lar heart rates. This can be achieved by oral and intravenous 
beta-blockade if necessary (calcium channel blockers and 
ivabradine can also be used). A bolus of contrast is injected 
intravenously, and using ECG gating, a coronary angiogram 
is obtained. CTCA provides excellent anatomical detail and 
has shown excellent diagnostic accuracy in comparison to 
ICA. CTCA is recommended for use in patients with low-to-
intermediate risk of CAD. This is predominantly because of 
its high sensitivity (95–99%) and negative predictive value 
(97–99%) but low specificity (64–83%).57,58
Beyond its low specificity, ionizing radiation dose and 
scan preparation, CTCA does have some other limitations. 
Scan accuracy is reduced in the presence of heavy calcifica-
tion, which can result in “blooming” artifact, which can make 
it difficult to interpret the study.59 In addition, CTCA is not as 
accurate in the diagnosis of in-stent restenosis, particularly 
in stents <3 mm.60 Because of this, CTCA is currently only 
recommended in low–intermediate-risk patients in the current 
guidelines, predominantly as a “rule-out” technique. Finally, 
CTCA is an anatomical technique, providing no functional 
information on stenosis severity. In the context of what is 
known about ICA, this does pose an issue. The Fractional 
Flow Reserve vs. Angiography for Guiding Percutaneous 
Coronary Intervention (FAME) trial demonstrated that use 
of FFR, an invasive measure of ischemia, leads to superior 
outcomes compared to visual stenosis assessment for guid-
ing intervention.61 This, in combination with the COURAGE 
trial, has led to an acceptance within cardiology that revascu-
larization in stable angina should preferentially be performed 
in functionally significant lesions only.62
Outcome data are also now emerging. The recent Prospec-
tive Multicenter Imaging Study for Evaluation of Chest Pain 
(PROMISE) trial was designed to compare outcomes in patients 
with CT vs. functional testing.63 In this trial of 10,003 inter-
mediate-risk patients, CTCA was associated with significantly 
fewer invasive angiograms with no significant CAD; however, 
patients in the CTCA arm were more likely to undergo ICA 
within 90 days. Clinical outcomes were not different between 
the two cohorts. The SCOT-HEART trial, which randomized 
4,146 patients with suspected angina to CTCA or standard care, 
revealed that CTCA changed management in many cases; how-
ever, it did not have any impact on readmission rates.64 There 
was also a reduction in MI with CTCA (26 vs. 42, p = 0.053).65 
Several observational  studies have also reported the prognostic 
significance of CAD identified on CTCA.66–68
Recently, two more novel techniques have been used 
to add functional assessment to CTCA and overcome this 
limitation. The first is CT perfusion imaging. This uses a 
similar principle to CMR perfusion, relying on the passage 
of (iodinated rather than gadolinium) contrast from the 
myocardial blood pool into the myocardium. Areas of infarc-
tion or ischemia appear hypointense compared to normal 
myocardium. Again, imaging can be performed at rest and 
stress to determine the functional significance of lesions.69 
CT perfusion requires optimal timing, as continuous imaging 
is not performed to reduce radiation dose, unlike in CMR. 
Diagnostic accuracy appears to be reasonable; however, due 
to limited availability and radiation dose concerns it has not 
yet been adopted into routine clinical practice.47
Another promising technique that is under investigation 
is CT fractional flow reserve (CTFFR). This technique uses 
computational fluid dynamics to provide a prediction of the 
invasive FFR. One advantage of this technique is that it requires 
no further imaging beyond a standard CTCA and also does 
not involve administration of adenosine to induce hyperemia. 
In the most studied technique, CT scans are sent to a CTFFR 
company, which provides an FFR in all major vessels at any 
point in the coronary tree within 24 hours. The methods for 
measuring CTFFR are however proprietary and somewhat 
time-consuming, requiring intense computational fluid dynam-
ics and computer modeling. In addition, there may be some 
reservations regarding sending studies to a separate company. 
Several companies however are working on CTFFR software 
which will be available on workstations to all clinicians. CTFFR 
has shown good reproducibility and diagnostic accuracy in 
several randomized trials. The Diagnosis of Ischemia-Causing 
Stenoses Obtained Via Noninvasive Fractional Flow Reserve 
(DISCOVER-FLOW) trial was the first proof of concept trial 
using a CTFFR in patients with known or suspected angina, 
reporting a diagnostic accuracy of 84.3% per vessel, and 87.4% 
per patient, with invasive FFR as the gold standard. Importantly, 
these were significantly improved compared to standard CTCA 
(58.5% and 61.2%, respectively).70 These promising results 
were also replicated in two further trials.71,72 The PLATFORM 
trial used CTFFR as part of a strategy comparing CTCA with 
standard care and found that CTCA led to reduced referrals for 
ICA and also had similar clinical outcomes at 1 year and lower 
cost than usual care.73,74 Further data are required however for 
this technique to reach routine clinical use.
Conclusion
Overall, a recent meta-analysis by Takx et al47 suggested 
that in comparison to FFR, CMR perfusion, PET and CT 
perfusion were better techniques for diagnosing CAD at 
both vessel and patient level than SPECT and stress echocar-
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diography. While SPECT and stress echo are both relatively 
cheap and widely available, as expertise is gained and more 
prognostic data become available, CMR, CT and PET may 
become more attractive for routine clinical practice. CT is 
quick and particularly useful in ruling out obstructive CAD, 
particularly in patients with low PTP; however, CMR and 
PET provide more information on myocardial structure and 
function. Figures 1 and 2 show a proposed management 
Figure 1 Proposed investigation algorithm for patients with suspected angina focusing on patients with low or high PTP of CAD.
Abbreviations: CAD, coronary artery disease; CTCA, computed tomography coronary angiography; ECG, echocardiography; ICA, invasive coronary angiography; PTP, 
pretest probability.
Patients with suspected CAD
Assess PTP
(history, examination, resting ECG)
Low PTP of
CAD
Intermediate PTP
of CADConsider noncardiac causes.
Exercise ECG or CTCA if CAD
requires exclusion
See figure 2
ICA - consider alternative
ischemia testing as per figure 2
if not suitable for ICA
High PTP of
CAD
Figure 2 Proposed investigation algorithm for patients with suspected angina and intermediate probability of CAD in an “ideal” hospital with all modalities available.
Abbreviations: CAD, coronary artery disease; CTCA, computed tomography coronary angiography; CTFFR, computed tomography fractional flow reserve; CMR, 
cardiovascular magnetic resonance; ECG, electrocardiogram; exECG, exercise ECG; SPECT, single-photon emission computed tomography.
Patients with intermediate
probability of CAD
Low-intermediate probability of
CAD
High-intermediate probability of
CAD
CTCA+/–CTFFR if available
exECG alternative
Contraindications
to CMR
No Yes
Suspicion of valvular
heart disease?
No
SPECT Stress
echocardiography
Yes
Stress CMR
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algorithm for the investigation of stable angina. This of course 
would need to be tailored dependent on the patient and the 
expertise available in the hospital. The ongoing ISCHEMIA 
trial (NCT01471522), which in contrast to both COURAGE 
and BARI-2D, will randomize patients to OMT or an inva-
sive strategy prior to ICA, but after noninvasive imaging 
has been performed will also provide further insights into 
the role of noninvasive imaging in stable CAD. While none 
of these techniques is likely to be the sole one used, in cor-
rectly identified appropriate patients, they will undoubtedly 
provide useful information with which to guide management.
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